Death from major cardiovascular diseases (ICD‐10: I11‐I13, I20‐I513, I60‐I69, I60‐I69) and other causes were assessed as competing outcomes.
Incidence, probability and prognostic factors of interruption by different causes were assessed by survival analysis and Cox regression model.
The RFPN prevalence in the general population, as well as their risk factors, was estimated, and in the reference centre the prevalence of proven specific causes was assessed.
Attributing one's smoking to genetic causes was assessed using four items, developed for this study, as no suitable measures existed.
In all cases, the temporal relationship between drug initiation and the occurrence of the reaction, the effect of drug cessation, and the possibility of other possible causes was assessed.
In addition, PFS (time between baseline and progression or death based on physician assessment or death from any cause) was assessed.
The prevalence of microalbuminuria and macroalbuminuria, and the predictive value of UACR for the primary composite outcome of each CHARM study--ie, death from cardiovascular causes or admission to hospital with worsening heart failure--and death from any cause were assessed.
Mortality from any cause was assessed by income and race (black or white).
Death due to any cause was assessed as the endpoint of OS; locoregional failure and distant metastasis were assessed as the endpoints of DSS.
